HomeAI · summaries
Storia in 9 fonti
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.
- ·
apnews.com
Experimental hepatitis B drug may offer 'functional cure' for some patients
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
- ·
statnews.com
Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
An experimental GSK drug helped 1 in 5 patients with chronic hepatitis B achieve what's known as a functional cure, vastly outpacing current treatments.
- ·
independent.co.uk
Experimental hepatitis B drug might offer 'functional cure' for a subset of patients
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
- ·
endpoints.news
GSK's functional cure data for hepatitis B drug are a major leap over standard of care
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews…
- ·
economictimes.indiatimes.com
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of…
- ·
morningstar.com
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic…
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
- ·
FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
- ·
cnn.com
Experimental hepatitis B drug might offer ‘functional cure’ for a subset of patients | CNN
A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s called a “functional cure,” researchers…
- ·
oglobo.globo.com
Nova injeção elimina completamente hepatite B em 20% dos pacientes
Tratamentos atuais proporcionam cura para apenas cerca de 1% das pessoas que vivem com o vírus de forma crônica